Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: A systematic review and meta-analysis
Lili Luo, Ting Luo, Mengyi Du, et al.
Journal of Infection (2021) Vol. 84, Iss. 3, pp. 418-467
Open Access | Times Cited: 12

Showing 12 citing articles:

SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
MacGregor Cox, Thomas P. Peacock, William T. Harvey, et al.
Nature Reviews Microbiology (2022) Vol. 21, Iss. 2, pp. 112-124
Open Access | Times Cited: 267
Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis
Guangyu Ao, Toni Li, Yushu Wang, et al.
Journal of Infection (2022) Vol. 85, Iss. 1, pp. e10-e12
Open Access | Times Cited: 11
Lack of Difference in Tocilizumab Efficacy in the Treatment of Severe COVID-19 Caused by Different SARS-CoV-2 Variants
Oleksandr Oliynyk, Wojciech Barg, Yanina Oliynyk, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 7, pp. 1103-1103
Open Access | Times Cited: 10
Application of Machine Learning in Hospitalized Patients with Severe COVID-19 Treated with Tocilizumab
Antonio Ramón, Marta Zaragozá, Ana María Torres, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 16, pp. 4729-4729
Open Access | Times Cited: 6
Factors predicting poor outcomes of patients treated with tocilizumab for COVID‑19‑associated pneumonia: A retrospective study
Vasiliki Georgakopoulou, Dimitrios Basoulis, Pantazis Voutsinas, et al.
Experimental and Therapeutic Medicine (2022) Vol. 24, Iss. 6
Open Access | Times Cited: 6
Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study
Luca Masotti, Giancarlo Landini, Grazia Panigada, et al.
International Immunopharmacology (2022) Vol. 107, pp. 108709-108709
Open Access | Times Cited: 5
Coronaviruses: Pandemic SARS-CoV-2
Benjamin J. Cowling, Sook‐San Wong
Springer eBooks (2024), pp. 1-79
Closed Access
Prolonged viral shedding in severely ill patients infected with SARS-CoV-2 Delta variants: A retrospective cohort study
Yae Jee Baek, Youn-Jung Lee, Jae Kim, et al.
Journal of Infection (2022) Vol. 85, Iss. 1, pp. 90-122
Open Access | Times Cited: 1
Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure
Luca Masotti, Elisa Cioni, Elisa Grifoni, et al.
European Journal of Internal Medicine (2022) Vol. 103, pp. 111-112
Open Access | Times Cited: 1
Injectable Porous Silicon Nanoparticles as a Plasma Cytokine Scavenger for Potentiating Cytokine Storm Syndrome Treatment
Ruogu Qi, Shengliang Li, Feng Li, et al.
Advanced NanoBiomed Research (2023) Vol. 3, Iss. 10
Open Access
Tocilizumab fails survival benefit in severe COVID-19 – A retrospective cohort study
Arjun Kumar, Rajat Ranka, Prasan Kumar Panda
Indian Journal of Physiology and Pharmacology (2022) Vol. 66, pp. 55-61
Open Access
Use of Tocilizumab in hospitalized patients during the first wave of the COVID-19 pandemic
Laura Álvarez-Arroyo, Francisco Javier Carrera‐Hueso, Montse Robustillo-Villarino, et al.
Ars Pharmaceutica (Internet) (2022) Vol. 63, Iss. 2, pp. 166-172
Open Access
Page 1

Scroll to top